Clinical Pharmacology

Clinical Pharmacology Publications

  1. Abdel-Rahman SM, Amidon GL, Kaul A, Lukacova V, Vinks AA, Knipp GT, Members of the BCSTF. Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group. Clin Ther. 2012; 34:S11-24.
  2. Chidambaran V, Sadhasivam S, Diepstraten J, Esslinger H, Cox S, Schnell BM, Samuels P, Inge T, Vinks AA, Knibbe CA. Evaluation of propofol anesthesia in morbidly obese children and adolescents. BMC Anesthesiol. 2013; 13:8.
  3. Chidambaran V, Venkatasubramanian R, Sadhasivam S, Esslinger HR, Cox SL, Diepstraten J, Fukuda T, Inge TH, Knibbe CA, Vinks AA. Pharmacokinetic and Pharmacodynamic Modeling of Propofol Depth of Anesthesia in Morbidly Obese Children. Clinical Pharmacology & Therapeutics. 2013; 93:S10-S10.
  4. Cohen M, Sadhasivam S, Vinks AA. Pharmacogenetics in perioperative medicine. Curr Opin Anaesthesiol. 2012; 25:419-27.
  5. Diepstraten J, Chidambaran V, Sadhasivam S, Esslinger HR, Cox SL, Inge TH, Knibbe CA, Vinks AA. Propofol clearance in morbidly obese children and adolescents: influence of age and body size. Clin Pharmacokinet. 2012; 51:543-51.
  6. Emoto C, Fukuda T, Cox S, Schniedewind B, Christians U, Vinks AA. Development of a Physiologically-Based Pharmacokinetics (Pbpk) Model for Sirolimus to Explain Inter-Patient Variability. Clinical Pharmacology & Therapeutics. 2013; 93:S40-S41.
  7. Emoto C, Yoda N, Uno Y, Iwasaki K, Umehara K, Kashiyama E, Yamazaki H. Comparison of p450 enzymes between cynomolgus monkeys and humans: p450 identities, protein contents, kinetic parameters, and potential for inhibitory profiles. Curr Drug Metab. 2013; 14:239-52.
  8. Fukuda T, Chidambaran V, Mizuno T, Venkatasubramanian R, Ngamprasertwong P, Esslinger HR, Vinks AA, Sadhasivam S. Organic Cation Transporter 1 Genetic Variants Contribute to Decreased Morphine Clearance in Children.. Clinical Pharmacology & Therapeutics. 2013; 93:S49-S49.
  9. Fukuda T, Goebel J, Cox S, Maseck D, Zhang K, Sherbotie JR, Ellis EN, James LP, Ward RM, Vinks AA. UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients. Ther Drug Monit. 2012; 34:671-9.
  10. Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Adamson PC, Childhood Absence Epilepsy Study T. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia. 2013; 54:141-55.
  11. Hayashi S, Ohashi K, Nakata E, Emoto C. Discovery of 1-(beta-amino substituted-beta-alanyl)-N,N-dimethylindoline-2-carboxamides as novel nonpeptide antagonists of nociceptin/orphanin FQ receptor: efficient design, synthesis, and structure-activity relationship studies. Eur J Med Chem. 2012; 55:228-42.
  12. Mizuno T, Fukuda T, Chidambaran V, Venkatasubramanian R, Niu J, Ngamprasertwong P, Esslinger HR, Vinks AA, Sadhasivam S. Genotype of Abcc3-211c > T Influences the Pharmacokinetics of Morphine Glucuronide in Children. Clinical Pharmacology & Therapeutics. 2013; 93:S63-S63.
  13. Mizuno T, Fukudo M, Terada T, Kamba T, Nakamura E, Ogawa O, Inui K, Katsura T. Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics. Drug Metab Pharmacokinet. 2012; 27:631-9.
  14. Ngamprasertwong P, Vinks AA, Boat A. Update in fetal anesthesia for the ex utero intrapartum treatment (EXIT) procedure. Int Anesthesiol Clin. 2012; 50:26-40.
  15. Sadhasivam S, Krekels EH, Chidambaran V, Esslinger HR, Ngamprasertwong P, Zhang K, Fukuda T, Vinks AA. Morphine clearance in children: does race or genetics matter?. J Opioid Manag. 2012; 8:217-26.
  16. Scott JR, Courter JD, Saldana SN, Widemann BC, Fisher M, Weiss B, Perentesis J, Vinks AA. Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1. Ther Drug Monit. 2013; 35:332-7.
  17. Sherwin CM, Saldana SN, Bies RR, Aman MG, Vinks AA. Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents. Ther Drug Monit. 2012; 34:535-44.
  18. Shimamoto Y, Fukuda T, Tominari S, Fukumoto K, Ueno K, Dong M, Tanaka K, Shirasaka T, Komori K. Decreased vancomycin clearance in patients with congestive heart failure. Eur J Clin Pharmacol. 2013; 69:449-57.
  19. Teusink A, Vinks A, Zhang KJ, Davies S, Filipovich A, Fukuda T, Nortman S, Kissell D, Dell S, Rhollans L, Mehta P. Impact of Pharmacogenetics and Therapeutic Drug Monitoring on Optimizing Voriconazole Dosing in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation. Pediatric Blood & Cancer. 2013; 60:S11-S11.
  20. Togashi Y, Masago K, Masuda S, Mizuno T, Fukudo M, Ikemi Y, Sakamori Y, Nagai H, Kim YH, Katsura T, Mishima M. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2012; 70:399-405.
  21. Vinks A. The Future of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure in Pregnant Women. CPT: Pharmacometrics & Systems Pharmacology. 2013; 2:e33.
  22. Wiles JR, Vinks AA, Akinbi H. Federal legislation and the advancement of neonatal drug studies. J Pediatr. 2013; 162:12-5.
  23. Yoda N, Emoto C, Date S, Kondo S, Miyake M, Nakazato S, Umehara K, Kashiyama E. Characterization of intestinal and hepatic P450 enzymes in cynomolgus monkeys with typical substrates and inhibitors for human P450 enzymes. Xenobiotica. 2012; 42:719-30.